Effects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary hypercholesterolemia

Matsunaga, Akira; Handa, Koichi; Mori, Tsukasa; Moriyama, Kengo; Hidaka, Kazuko; Yuki, Mika; Sasaki, Jun; Arakawa, Kikuo

doi:10.1016/0021-9150(92)90249-g

Cited by 22 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High dose nicotinic acid (2 g) reduces the Lp(a) concentration up to ∼17% . However, this treatment is not generally well tolerated because a significant number of patients experience flushing.…”

mentioning

confidence: 99%

Does Regular Lipid Apheresis in Patients With Isolated Elevated Lipoprotein(a) Levels Reduce the Incidence of Cardiovascular Events?

et al. 2013

View full text Add to dashboard Cite

Elevated lipoprotein(a) (Lp(a)) is known as an independent risk factor for atherosclerosis and cardiovascular events. Regular lipid apheresis decreases elevated Lp(a) concentrations. However, there is a lack of reliable data regarding the effect of lipid apheresis on cardiovascular endpoints. To assess the effects of apheresis, we compared the occurrence of cardiovascular events in 37 patients treated regularly with lipid apheresis at the time periods of preinitiation of apheresis and during apheresis treatment. A retrospective analysis of 37 patients (35 men and two women; aged 58 years ± 11 [mean ± standard deviation]; body mass index 26 kg/m 2 ± 3; low-density lipoprotein (LDL)-cholesterol before apheresis 84 mg/dL ± 21; Lp(a) before apheresis 112 mg/dL ± 34) treated regularly with lipid apheresis was performed. Patients' medical records were screened for cardiovascular events at the preapheresis and during apheresis periods.Apheresis led to a significant reduction of lipid levels (LDL cholesterol −60%; Lp(a) -68%) measured after apheresis. The eventfree survival rate after 1 year in the preapheresis period was 38% (22-54%, 95% confidence interval [CI]) vs. 75% (61-89%, 95% CI) in the during-apheresis period with a statistically significant difference (P < 0.0001). Apheresis seems to lower the progression of atherosclerosis leading to a reduced number of cardiovascular events in hyperlipoproteinemia(a). Because prospective and controlled trials are lacking, the therapeutic effectiveness of lipid apheresis can only be estimated.

show abstract

mentioning

confidence: 99%

Does Regular Lipid Apheresis in Patients With Isolated Elevated Lipoprotein(a) Levels Reduce the Incidence of Cardiovascular Events?

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Nicotinic acid monotherapy (3.0 g/day) causes a decrease in the TG level by 26% 688 ) . Nicotinic acid derivatives also have Lp(a)-lowering effects 689 – 691 ) . The main adverse drug reactions include itching and facial flushing because of peripheral vasodilation.…”

Section: Comprehensive Risk Managementmentioning

confidence: 99%

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017

Kinoshita

Yokote

Arai

et al. 2018

J Atheroscler Thromb

622

569

View full text Add to dashboard Cite

“…Nicotinic acid alone (3.0 g/day) has a TG lowering rate of 26% 1196) . Nicotinic acid derivatives also have a lowering effect on Lp(a) [1196][1197][1198] . Major side effects include itching, facial flushing due to peripheral vasodilation, and hyperuricemia.…”

Section: Advance Publication Journal Of Atherosclerosis and Thrombosismentioning

confidence: 99%

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022

Okamura,

Tsukamoto,

Arai

et al. 2024

JAT

View full text Add to dashboard Cite

Effects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary hypercholesterolemia

Cited by 22 publications

References 29 publications

Does Regular Lipid Apheresis in Patients With Isolated Elevated Lipoprotein(a) Levels Reduce the Incidence of Cardiovascular Events?

Does Regular Lipid Apheresis in Patients With Isolated Elevated Lipoprotein(a) Levels Reduce the Incidence of Cardiovascular Events?

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022

Contact Info

Product

Resources

About